Amcor plc (AMCR)
Key Takeaways:
Company Overview
Amcor plc is a global packaging company focused on responsible primary packaging and dispensing solutions for nutrition, health, beauty, wellness, and healthcare end markets. Following the Berry Global merger, the business is now materially larger and more diversified, spanning flexible packaging, rigid packaging, closures, dispensing systems, and pharma delivery devices across more than 40 countries. Its model is built on direct customer relationships, material science, technical design, and sustainability-led innovation, with heavy emphasis on recyclable, reusable, or compostable packaging formats and recycled-content targets. The company also has a sizable R&D footprint, a broad patent base, and a global manufacturing network that supports local-for-local supply. However, the business is still exposed to low-growth, highly competitive packaging markets, raw-material inflation, regulatory pressure on plastics, and meaningful leverage from the Berry transaction. Integration execution, synergy realization, and portfolio rationalization will likely be more important than headline revenue growth. This remains a cash-generative industrial franchise, but it is not a low-risk one: debt, execution, and regulatory burdens materially constrain the investment case.
Business Segments
Economic Moat Analysis
Amcor has a real but not elite competitive advantage. Its moat is primarily built on scale, customer integration, technical expertise, and the operational complexity of serving regulated global packaging markets. These traits support resilience and help defend share, but packaging remains a highly competitive industry with limited structural pricing power. The Berry merger improves size and breadth, yet it also adds debt, integration risk, and execution complexity. On balance, the moat is best classified as narrow: durable enough to support cash generation, but not strong enough to prevent cyclical pressure, price competition, or regulatory disruption.
Amcor’s global manufacturing and procurement scale should support better cost leverage, customer coverage, and capital efficiency than smaller peers.
Packaging is deeply embedded in customer operations, but switching is still possible over time, especially when price pressure rises.
Long-standing direct relationships, technical collaboration, and service capabilities create stickiness, particularly for regulated and high-spec applications.
A large patent base, R&D spending, and material-science capabilities help differentiate products, though innovation alone does not fully insulate the business from commoditization.
Compliance expertise in food, healthcare, sustainability, and global EHS requirements raises barriers for some rivals, but also increases Amcor’s own cost burden.
A broad global footprint and local manufacturing model improve service and resilience, but this is an operational advantage more than an impenetrable moat.
Key Strengths
- Scale Advantage: The Berry merger created a much larger global platform, improving purchasing power, customer reach, and manufacturing density across flexible and rigid packaging.
- End-Market Resilience: Exposure to food, beverage, health, and personal care packaging provides demand that is more defensive than many industrial sectors.
- Innovation Base: The company spends heavily on R&D and holds thousands of patents, registered designs, and trademarks, supporting continuous product differentiation.
- Customer Integration: Direct sales, technical support, and co-development capabilities make Amcor embedded in customer supply chains and harder to replace quickly.
- Cash Generation: Operating cash flow remains robust, supporting dividends, debt service, restructuring, and selective reinvestment.
- Sustainability Positioning: The company has invested for years in recyclable, reusable, and recycled-content packaging, which matters for large multinational customers.
- Geographic Diversification: A broad global footprint reduces reliance on any single market, customer, or regulatory regime.
- Pricing Mechanisms: In many cases, raw-material cost inflation can be passed through over time via contractual pricing structures.
Identified Weaknesses
- High Leverage: Debt remains substantial after the Berry acquisition, which reduces financial flexibility and increases sensitivity to rates and refinancing conditions.
- Integration Burden: The Berry merger adds execution risk, restructuring costs, cultural integration challenges, and the possibility of underdelivered synergies.
- Margin Pressure: Packaging is structurally competitive, and Amcor still faces price pressure despite its scale and innovation claims.
- Dilution Risk: The merger materially increased share count, which can dilute per-share benefits even when absolute earnings improve.
- Complex Accounting: Large amortization, integration charges, and non-GAAP adjustments make underlying earnings quality harder to judge.
- Weak Organic Volume: Excluding merger and currency effects, recent sales trends still showed declining underlying volumes in several areas.
- Regulatory Exposure: Plastics, recycling, EPR, PFAS, and ESG-related rules can raise compliance costs and constrain certain product lines.
- Labor Complexity: A large share of employees are unionized or covered by collective bargaining agreements, increasing wage and disruption risk.
Growth Opportunities
- Synergy Realization: The Berry combination offers sizable procurement, manufacturing, G&A, and financial synergy potential if execution remains disciplined.
- Portfolio Optimization: Divestitures of non-core assets could improve growth, margin quality, and capital allocation efficiency.
- Higher-Value Mix: Shifting toward faster-growing health, beauty, and wellness categories could support better margins over time.
- Sustainability Demand: Large customers increasingly want lower-carbon and recyclable packaging, creating room for premium solutions if Amcor can deliver at scale.
- Innovation Upside: New materials, dispensing technologies, and barrier solutions may allow selective share gains in more attractive niches.
- Working Capital Improvement: A larger, more integrated platform may unlock supply-chain efficiency and inventory benefits if management executes well.
- Emerging Market Growth: Long-term packaging demand in selected emerging markets can grow faster than developed-market consumption, albeit with higher risk.
- Debt Deleveraging: If cash flow stays strong and divestitures proceed, leverage could gradually decline, improving equity optionality.
Risk Factors
- Weak Consumer Demand: Softer consumption and order volatility can pressure volumes, especially in discretionary or branded categories.
- Raw Material Shock: Resin, aluminum, paper, energy, and logistics costs remain volatile and can compress margins before pass-through catches up.
- Trade Policy Risk: Tariffs, customs changes, and retaliatory trade actions can disrupt sourcing, pricing, and customer demand.
- Geopolitical Disruption: Middle East conflict, global shipping disruptions, and regional instability can hurt supply chains and input costs.
- Interest Rate Pressure: Higher rates increase borrowing costs and refinancing risk for a heavily indebted balance sheet.
- Regulatory Tightening: Restrictions on plastics, PFAS, carbon, recycling obligations, and human-rights reporting can increase costs or eliminate product demand.
- Integration Failure: If Berry synergies slip or restructuring drags, the acquisition could destroy value rather than create it.
- Cyber and IT Risk: A global manufacturing footprint and multiple ERP systems increase exposure to cyberattacks and operational outages.
Valuation Metrics
AMCR trades at P/E (ttm) 17.56 with Forward P/E not provided. That’s a mid-to-slightly rich valuation for a more mature industrial/packaging business; it’s not “deep value,” so margin/earnings durability matters.
Price-to-sales is P/S 0.82 (and EV/Sales 0.76), which is valuation-positive versus many peers and suggests the market isn’t pricing exuberant revenue growth.
Price-to-book is P/B 1.64. This is higher than 1, implying either (a) balance sheet strength is being valued, or (b) book value is relatively compressed vs earnings power.
Cash build is reasonable: Cash/sh 2.41 (dividend excluded). This can cushion downside and helps explain the not-extreme EV/Sales.
Cash-flow valuation: P/FCF 15.04. Without a stated FCF growth rate, this looks like a “paying for current cash generation” rather than a bargain on future free cash flows.
Earnings/valuation growth link: PEG not provided. So we can’t confirm whether the P/E is justified by growth expectations.
Enterprise multiple: EV/EBITDA 17.36 is on the higher side relative to the low EV/Sales, which can happen when margins are improving or when EBITDA is not as suppressed as revenue.
Earnings & Profitability
Profitability is mixed-to-okay and important to validate: ROA 1.84%, ROE 1.84% (given ROE column appears close to ROA), and ROIC 4.71%. These are not “high-quality compounder” levels, but they’re not catastrophic either.
Margins: Gross margin 32.08%, Operating margin 25.92%, Profit margin 56.62%. Note: a profit margin of 56.62% alongside moderate ROA/ROIC can indicate data/mapping issues, or that the profit metric is not strictly “net income margin.” Treat this metric cautiously.
Earnings quality/consistency: EPS past 3/5Y is -12.38% and EPS past 3/5Y is shown as -12.38% -4.62% (downtrend). This suggests earnings have been under pressure over the recent period.
Forward earnings placeholders are incomplete: many next-period EPS fields are missing/“-”. Because forward visibility is limited, valuation support relies more on current margins and revenue trends.
Growth Analysis
Revenue growth is currently positive: Sales Y/Y (TTM) 12.82% and Sales past 3/5Y 16.95% (as provided). This is a constructive growth signal for a value investor.
Earnings growth appears weaker/negative: EPS Y/Y (TTM) 4.17% but the “EPS past 3/5Y” shows negative ranges (e.g., -12.38%). That mismatch implies revenue has grown faster than EPS, likely from cost inflation, mix, or restructuring.
Quarterly momentum: EPS Q/Q 0.00% and Sales Q/Q 0.27% are essentially flat/low, suggesting near-term momentum is not strong.
Long-term growth expectations are unclear: EPS next 5Y not provided, so PEG-style justification can’t be computed from your data.
Financial Health
Liquidity looks solid: Quick ratio 1.25 and Current ratio 1.28. This reduces short-term refinancing risk.
Leverage: Debt/Eq 1.25 and LT Debt/Eq 1.28 (both >1). This indicates a leveraged capital structure, which can magnify earnings volatility if margins compress.
Enterprise coverage: valuation metrics (EV/Sales 0.76) suggest the market is not overly distressed, but leverage means earnings resilience is crucial.
Outstanding shares: Shs Outstand 461.90M. No buyback signal is provided, but share count stability would be a factor to check (not available here).
Ownership Structure
Insider ownership: Insider Own 2.38% (moderate). Insider ownership at this level suggests insiders have skin in the game, but it’s not dominant.
Insider transactions not provided meaningfully (Insider Trans 0.00%), so we can’t infer strong insider sentiment.
Institutional ownership: Inst Own 81.85%. This indicates institutional control/attention and generally supports liquidity and governance oversight.
Institutional transactions: Inst Trans 1.84% indicates some level of recent activity (direction not provided in your data).
Market Performance
Price level and trading context: Price 42.46 with 52W high 49.63 and 52W low 41.86. The stock is near the 52-week low, implying the market may already be pricing caution.
Trend vs moving averages: SMA20 41.86, SMA50 41.86, SMA200 41.86. This alignment suggests the stock recently consolidated around the long-run average area (data looks rounded/possibly duplicated, but directionally it indicates no extended uptrend).
Recent performance: Perf week 2.37%, Perf month 0.95%, Perf quarter 37.97%? (your line is confusing: there are two series values). Clear bottom-line from your table: Perf YTD -8.78% (negative), and Perf 3Y -27.77% (negative).
Given negative multi-year performance, the stock may be in a “turnaround/repair” phase rather than a sustained compounder phase.
Momentum & Volatility
Volatility and risk: Volatility 36.25 (as shown), with ATR 2.09. This suggests non-trivial daily swing capacity; position sizing matters.
Beta: Beta 0.57, implying lower market sensitivity than the broad index (defensive tilt).
Relative volume: Rel Volume 0.95 and Avg Volume 21.54M vs Volume 50.94 (your last columns look inconsistent; treat exact volume with caution). Directionally, there’s no clear exceptional spike from provided fields.
RSI: RSI (14) 42.46, leaning bearish/neutral (below 50), consistent with price being near 52W lows.
Momentum summary: Near 52W lows with sub-50 RSI indicates no strong bullish momentum yet; upside likely depends on earnings stabilization.
Investment Recommendations
value Investor:
With valuation support from P/S 0.82 and near-52W-low pricing, a value-style entry makes sense closer to the lower end of the recent range. I’d target $40.50–$41.50 first (near/just below the 52W low area ~41.86), and add only if fundamentals stabilize (EPS trend stops deteriorating).
growth Investor:
For growth-oriented entry, demand a better “quality + momentum” setup because earnings growth has been weaker recently (EPS trend negative over 3/5Y). I’d target $42.00–$43.00 only if technicals/earnings confirm (e.g., improving EPS/operating margin trajectory). If price breaks below $41.86, wait for a clearer reversal before adding.
Investment Summary
AMCR screens cheap on sales (P/S 0.82; EV/Sales 0.76) but not deep on earnings (P/E 17.56; P/FCF 15.04) with leverage (Debt/Eq ~1.25). Revenue growth looks solid (Sales Y/Y +12.82%), while EPS multi-year trend appears weaker. ROIC 4.71% and moderate margins suggest “turnaround/cycle sensitivity.” Value: consider entry near $40.5–$41.5. Growth: only add around $42–$43 if EPS stabilizes.